Hyperprogressive disease: a distinct effect of immunotherapy?

Vinita Popat¹, David E Gerber^{2

3

4}

Affiliations

¹ School of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
² Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
³ Department of Clinical Sciences UT Southwestern Medical Center, Dallas, Texas, USA.
⁴ Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.

Editorial

Vinita Popat et al. J Thorac Dis. 2019 Mar.

. 2019 Mar;11(Suppl 3):S262-S265.

doi: 10.21037/jtd.2019.01.97.

Vinita Popat¹, David E Gerber^{2

3

4}

¹ School of Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
² Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas, USA.
³ Department of Clinical Sciences UT Southwestern Medical Center, Dallas, Texas, USA.
⁴ Harold C. Simmons Comprehensive Cancer Center, UT Southwestern Medical Center, Dallas, Texas, USA.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C. Ferrara R, et al. JAMA Oncol. 2018 Nov 1;4(11):1543-1552. doi: 10.1001/jamaoncol.2018.3676. JAMA Oncol. 2018. PMID: 30193240 Free PMC article.

1. Kelly K, Chansky K, Gaspar LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008;26:2450-6. 10.1200/JCO.2007.14.4824 - DOI - PubMed
1. Ludovini V, Bianconi F, Pistola L, et al. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer. J Thorac Oncol 2011;6:707-15. 10.1097/JTO.0b013e31820a3a6b - DOI - PubMed
1. Champiat S, Dercle L, Ammari S, et al. Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res 2017;23:1920-8. 10.1158/1078-0432.CCR-16-1741 - DOI - PubMed
1. Ferrara R, Mezquita L, Texier M, et al. Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol 2018;4:1543-52. 10.1001/jamaoncol.2018.3676 - DOI - PMC - PubMed
1. Tazdait M, Mezquita L, Lahmar J, et al. Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. Eur J Cancer 2018;88:38-47. 10.1016/j.ejca.2017.10.017 - DOI - PubMed